Amarin Corporation (AMRN) Announces Publication of MARINE Phase 3 Data
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Up)Join SI Premium – FREE
Amarin Corporation plc (Nasdaq: AMRN), announced that results of its pivotal MARINE Phase 3 clinical trial were published in the September issue of The American Journal of Cardiology.
The Company also reported, as previously announced, that data from the Company's Phase 3 MARINE trial was presented at the European Society of Cardiology Congress 2011.
The Company also reported, as previously announced, that data from the Company's Phase 3 MARINE trial was presented at the European Society of Cardiology Congress 2011.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aligos Therapeutics Inc. (ALGS) Presents Positive Data from the ALG-097558 Phase 1 Study
- Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
- T-Mobile posts mixed Q1 top and bottom line, expects more subscribers in 2024
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
